



SASKATCHEWAN FORMULARY COMMITTEE BULLETIN 53rd Edition

NEW EXCEPTION DRUG STATUS AGENTS

Effective July 1, 2003 the following product is available under Exception Drug Status subject to the indicated criteria:

Anakinra, subcutaneous injection (pre-filled syringe), 100mg/0.67mL (Kineret-AMG)

- For treatment of patients with active rheumatoid arthritis who have failed or are intolerant to methotrexate and leflunomide. (Note - exceptions can be considered in cases where methotrexate or leflunomide are contraindicated). *This product should be used in consultation with a specialist in this area.*
Note: Coverage will not be provided when used in combination with TNF blocking agents (i.e. infliximab and etanercept) due to the significantly higher risk of adverse events.

NEW DOSAGE FORMS/ STRENGTHS OF EXCEPTION DRUG STATUS AGENTS

Effective July 1, 2003 the following product will be covered under the same Exception Drug Status criteria as the currently listed forms/strengths:

Risedronate sodium, tablet, 35mg (Actonel-PGA)

- See revised criteria (this page) for risedronate 5mg, 35mg

NEW FULL FORMULARY LISTINGS:

- Latanoprost/timolol maleate, ophthalmic solution (2.5mL), 50ug/mL/5mg/mL (Xalacom-PHU)

- Glucose oxidase/peroxidase reagent, strip (Precision Easy-ABB)
- Erythromycin/benzoyl peroxide 3%/5%, topical gel (Benzamycin-DER)
- Valsartan/Hydrochlorothiazide, tablet, 160mg/25mg (Diovan HCT-NVR)
- Valsartan, tablet, 80mg, 160mg (Diovan-NVR)

NEW INTERCHANGEABLE EXCEPTION DRUG STATUS AGENT

Effective July 1, 2003 the following product will be covered under the same Exception Drug Status criteria as Acular:

Ketorolac tromethamine, ophthalmic solution, 0.5% (Apo-Ketorolac-APX)

PLEASE NOTE:

This product will not appear in the new edition of the Formulary as supply was not available at time of print. Product is currently available.

NEW FULL FORMULARY INTERCHANGEABLE LISTINGS

- Metformin, tablet, 500mg, 850mg (RhoXal-Metformin-RHO)
- Pravastatin, tablet, 10mg, 20mg, 40mg (Novo-Pravastatin-NOP)
- Lovastatin, tablet, 20mg, 40mg (Novo-Lovastatin-NOP)
- Medroxyprogesterone, 2.5mg, 5mg, 10mg (pms-Medroxyprogesterone-PMS)
- Fluconazole, capsule, 150mg (pms-Fluconazole-PMS)

- Aminonide, topical cream, 0.1% (Amcort-TAR)
- Nizatidine, capsule, 150mg, 300mg (Nu-Nizatidine-NXP)
- Simvastatin, tablet, 5mg, 10mg, 20mg, 40mg, 80mg (Nu-Simvastatin-NXP)
- Sertraline, capsule, 25mg, 50mg, 100mg (Nu-Sertraline-NXP)
- Pravastatin, tablet, 10mg, 20mg, 40mg (ratio-Pravastatin-RTP)
- Benzotropine mesylate, 1mg/mL injection solution (2mL) (Benzotropine Omega-OMG)
- Simvastatin, tablet, 5mg, 10mg, 20mg, 40mg, 80mg (Simvastatin-PRM)
- Terbinafine HCl, tablet, 250mg (Terbinafine-PRM)
- Medroxyprogesterone, tablet, 2.5mg, 5mg, 10mg (Dom-Medroxyprogesterone-DOM)
- Lovastatin, tablet, 20mg, 40mg (Dom-Lovastatin-DOM)
- Hydrochlorothiazide, tablet, 25mg, 50mg (Bio-Hydrochlorothiazide-BMD)
- Furosemide, tablet, 20mg, 40mg (Bio-Furosemide-BMD)
- Sodium aurothiomalate, inj. sol. (1mL), 10mg/mL, 25mg/mL, 50mg/mL (Sodium Aurothiomalate-SAB)

MODIFICATIONS TO CURRENT EXCEPTION DRUG STATUS CRITERIA

Effective July 1, 2003 the Exception Drug status criteria for the following products are modified as indicated:

Meloxicam, tablet, 7.5mg, 15mg (Mobicox-BOE)

- For the treatment of patients with an intolerance to other NSAIDs listed in the formulary.

Alendronate sodium, tablet 10mg, 70mg (Fosamax-MSD)

- For treatment of osteoporosis in patients who do not respond to etidronate disodium/calcium (Didrocal) after receiving it for one year.
- For treatment of osteoporosis in patients unable to tolerate etidronate disodium/calcium (Didrocal).
- For the treatment of osteoporosis in patients who have pre-existing and/or recent fractures.

Risedronate sodium, tablet, 5mg, 35mg (Actonel-PGA)

- For treatment of osteoporosis in patients who do not respond to etidronate disodium/calcium (Didrocal) after receiving it for one year.
- For treatment of osteoporosis in patients unable to tolerate etidronate disodium/calcium (Didrocal).
- For the treatment of osteoporosis in patients who have pre-existing and/or recent fractures.

Clonidine HCl, tablet, 0.025mg (Dixarit-BOE)

- For treatment of menopausal flushing.
- For treatment of Attention Deficit Hyperactivity Disorder.

Tacrolimus, topical ointment, 0.03%, 0.1% (Protopic-FUJ)

- For the treatment of moderate to severe atopic dermatitis in patients who have been unresponsive or intolerant to topical prescription steroids within the last three months.

Clopidogrel bisulfate, tablet, 75mg (Plavix-SAW)

- For treatment of patients who have experienced a transient ischemic attack, stroke, or a myocardial infarction while on acetylsalicylic acid.

- For treatment of patients who have experienced a transient ischemic attack, stroke, or who have had a myocardial infarction and have a clearly demonstrated allergy to acetylsalicylic acid (manifested by asthma or nasal polyps).
- For treatment of patients who have experienced a transient ischemic attack, stroke or have had a myocardial infarction and are intolerant of acetylsalicylic acid (manifested by gastrointestinal hemorrhage).
- When prescribed following intracoronary stent placement, coverage will be provided for a period of 1 year. In patients intolerant or allergic to ASA coverage may be renewed.
- For reduction of atherothrombotic events in patients with acute coronary syndrome (i.e. unstable angina or non-Q-wave myocardial infarction without ST segment elevation) concurrently with acetylsalicylic acid. Coverage will also be considered for patients intolerant or allergic to acetylsalicylic acid. Coverage will be provided for a period of 1 year. In patients intolerant or allergic to ASA coverage may be renewed.

Ticlopidine HCl, 250mg (Ticlid-HLR) (Apo-Ticlopidine-APX) (Nu-Ticlopidine-NXP) (Gen-Ticlopidine-GPM) (pms-Ticlopidine-PMS) (Dom-Ticlopidine-DOM) (Rhoal-Ticlopidine-RHO) (Novo-Ticlopidine-NOP)

- For treatment of patients who have experienced a transient ischemic attack, stroke, or myocardial infarction while on acetylsalicylic acid.
- For treatment of patients who have experienced a transient ischemic attack, stroke, or myocardial infarction and have a

- clearly demonstrated allergy to acetylsalicylic acid (manifested by asthma or nasal polyps).
- For treatment of patients who have experienced a transient ischemic attack, stroke, or myocardial infarction and are intolerant of acetylsalicylic acid (manifested by gastrointestinal hemorrhage).

SOME OF THE PRODUCTS CURRENTLY UNDER REVIEW BY THE FORMULARY COMMITTEE

- Hydromorphone HCl, controlled-release capsule, 12mg, 16mg, 24mg (Palladone XL-PFR)
- Cyclosporine, liquid, 100mg/mL (Apo-Cyclosporine-APX)
- Cyclosporine, capsule, 100mg (Rhoal-Cyclosporine-RHO)
- Valdecoxib, tablet, 10mg, 20mg (Bextra-PHU)
- Rosuvastatin, 10mg, 20mg, 40mg (Crestor-AST)
- Clozapine, tablet, 25mg, 100mg (Gen-Clozapine-GPM)
- Rosiglitazone maleate/metformin HCl, tablet, 1mg/500mg, 2mg/500mg, 4mg/500mg (Avandamet-GSK)
- Sirolimus, tablet, 1mg (Rapamune-WYA)
- Tiotropium bromide monohydrate, powder capsule, 18ug/dose (Spiriva-BOE)

PLEASE NOTE: triamcinolone hexacetonide, injection suspension, 20mg/mL (Aristospan-STI) and stilboestrol, tablet, 0.1mg, 0.5mg, 1mg (Stilboestrol-WEL) have been in short supply for some time. The manufacturers of these products have indicated there will be no supply of these products for several months.

**Saskatchewan Formulary Committee
2nd Floor, 3475 Albert Street
Regina, Saskatchewan S4S 6X6**

This Bulletin is not to be reproduced or republished except with the approval of the Saskatchewan Formulary Committee. Inquiries should be directed to the address shown at left.